Similarly, monoclonal antibodies targeting IFN-α (sifalimumab) (72) or IFNAR1 (anifrolumab) (73) and specific ablation of pDCs, which are the main IFN-I producing cells (74), may also have therapeutic value in obese individuals in addition to SLE patients in view of the importance of the pDC-IFN-I axis in obesity. The gene discussed is IFNA1; the disease is systemic lupus erythematosus.